TAK
Takeda Pharmaceutical Company Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -25.0% ·
share flow +11.4% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +7 | 88.72M | $1.46B | +9 | −2 |
| Q1 2026 | 81 | +2 | 81.32M | $1.54B | +7 | −5 |
| Q4 2025 | 79 | -2 | 68.50M | $1.10B | — | −2 |
| Q3 2025 | 14 | +2 | 31.18M | $456.42M | +3 | −1 |
| Q2 2025 | 9 | -3 | 18.36M | $283.88M | — | −3 |
| Q1 2025 | 9 | +1 | 8.73M | $129.81M | +2 | −1 |
| Q4 2024 | 8 | +3 | 9.62M | $127.30M | +4 | −1 |
| Q3 2024 | 5 | 0 | 11.53M | $98.50M | +1 | −1 |
| Q2 2024 | 5 | — | 10.02M | $129.64M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.10M | — | $63.41M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 4.10M | — | $63.41M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 4.10M | — | $63.41M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 4.10M | — | $63.41M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 3.55M | — | $54.90M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 3.55M | — | $54.90M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 3.55M | — | $54.90M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 3.30M | +4.5% | $51.01M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 9 | Millennium Management ✦ | 3.09M | +1152.2% | $47.75M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 2.53M | -26.2% | $39.17M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 11 | Arrowstreet Capital ✦ | 1.22M | -13.0% | $18.84M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 369.14K | +88.6% | $5.71M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 369.14K | +88.6% | $5.71M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 369.14K | +88.6% | $5.71M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passive) | 101.87K | — | $1.57M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Fisher Asset Management ✦ | 98.64K | +89.2% | $1.52M | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $2.12M | was 0.0% |
| D. E. Shaw & Co. | $833,255 | was 0.0% |
| Marshall Wace | $672,823 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 356 holders, 97.72M shares, $1.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 19.65K sh · $363,347
Officer · 12.98K sh · $235,118
Officer · 50.01K sh · $855,205
Officer · 47.59K sh · $813,721
Officer · 14.01K sh · $239,503
Officer · 30.87K sh · $527,843
Officer · 975 sh · $17,062
Officer · 33.63K sh · $588,715
Officer · 6.77K sh · $115,835
Officer · 7.28K sh · $124,437
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology